Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.58 |
| ▸ | DRD4 | P21917 | 6/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14203051 | 1.00 | SLC6A2 (0.58) | SLC6A2DRD4DRD2DRD3SIGMAR1 | |
| SCHEMBL5045984 | 1.00 | SLC6A2 (0.58) | SLC6A2DRD4DRD2DRD3SIGMAR1 | |
| SCHEMBL14202970 | 1.00 | SLC6A2 (0.58) | SLC6A2DRD4DRD2DRD3SIGMAR1 | |
| SCHEMBL5042305 | 0.88 | SLC6A2 (0.59) | SLC6A2DRD4DRD2DRD3SIGMAR1 | |
| SCHEMBL14203009 | 0.88 | SLC6A2 (0.59) | SLC6A2DRD4DRD2DRD3SIGMAR1 | |
| SCHEMBL5044079 | 0.87 | SLC6A2 (0.56) | SLC6A2DRD4DRD2DRD3CYP1A2 | |
| SCHEMBL14203043 | 0.87 | SLC6A2 (0.56) | SLC6A2DRD4DRD2DRD3CYP1A2 | |
| SCHEMBL14612497 | 0.87 | SLC6A2 (0.56) | SLC6A2DRD4DRD2DRD3CYP1A2 | |
| SCHEMBL5437818 | 0.87 | SLC6A2 (0.45) | SLC6A2DRD4DRD2DRD3SIGMAR1 | |
| SCHEMBL14203040 | 0.87 | SLC6A2 (0.45) | SLC6A2DRD4DRD2DRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |